Vertex Pharmaceuticals Incorporated
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Vertex Pharmaceuticals Incorporated sits in the top decile of US sponsors by registered trial count (#156 of 15,742 sponsors by registered trial count).
Vertex Pharmaceuticals Incorporated: 191 sponsored US clinical trials, 20 recruiting.
Vertex Pharmaceuticals Incorporated sponsors 191 registered US clinical trials on ClinicalTrials.gov, 20 of them currently recruiting, and 144 completed. 67 of these trials are in Phase 3-4 (later-stage) and 119 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cystic Fibrosis, with 20 trials.
Top-decile sponsor footprint
Vertex Pharmaceuticals Incorporated ranks in the top decile of sponsors by registered trial count (#156 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
144 of 161 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
191 total, page 1 of 4
A Phase 1, First-in-human Study of VX-433
NCT07584434
A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
NCT07501702
Evaluation of Pain Treatment After Total Knee Arthroplasty
NCT07538570
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
NCT07437105
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
NCT07378865
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
NCT07283770
Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
NCT07231419
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275
An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant
NCT06832410
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
NCT06794996
Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT06619860
Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
NCT06628908
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
NCT06185764
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
NCT06154447
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
NCT05668741
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT05477563
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT05422222
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
NCT05312879
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT04786262
Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
NCT07570069
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
NCT07349394
Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants
NCT07074327
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
NCT07022119
Polycystic Kidney Disease 1 (PKD1) Gene Variant Groups in Autosomal Dominant Polycystic Kidney Disease
NCT06747572
Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
NCT06696443
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
NCT05791201
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
NCT05356195
Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD)
NCT05329649
A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
NCT07010406
A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation
NCT06861413
A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries
NCT06887959
A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
NCT06887972
A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose
NCT06886269
A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists
NCT06834009
Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants
NCT06820307
A Study Evaluating Efficacy and Safety of VX-993 for Acute Pain After a Bunionectomy
NCT06619847
A Phase 1 Dose Escalation Study of VX-973 in Healthy Participants
NCT06615570
Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment
NCT06529796
Evaluation of the Pharmacokinetic Drug-drug Interactions Between VX-993 and Metformin in Healthy Adults
NCT06523595
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
NCT06508762
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT06506773
A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults
NCT06394167
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
NCT06345755
A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation
NCT06312787
A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine
NCT06336096
A Study of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) in Healthy Adult Panelists
NCT06299696
A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)
NCT06299709
A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993
NCT06226454
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 62 |
| Phase 2 | 57 |
| Phase 3 | 62 |
| Phase 4 | 5 |
What is open in the Vertex Pharmaceuticals Incorporated pipeline
20 recruiting of 191 indexed (10% open); 144 completed (75%).
Phase mix: 67 late (III/IV) vs 119 early (I/II) (early-phase heavy).
Top condition: Cystic Fibrosis (20 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vertex Pharmaceuticals Incorporated: open-pipeline peers nationwide
Peers matched on 191 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Vertex Pharmaceuticals Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 191 trials (± recruiting share)
- Vanderbilt-Ingram Cancer Center · 189 trials · 15% recruiting
- Hospital for Special Surgery, New York · 194 trials · 18% recruiting
- Nationwide Children's Hospital · 188 trials · 15% recruiting
- Arizona State University · 187 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Alexion Pharmaceuticals · 10% recruiting · 162 trials
- Zimmer Biomet · 10% recruiting · 115 trials
- University of Mississippi Medical Center · 10% recruiting · 96 trials
- Bastyr University · 11% recruiting · 19 trials
Related
What to do with this Vertex Pharmaceuticals Incorporated page
191 registered trials is a research-attention snapshot, not an endorsement of Vertex Pharmaceuticals Incorporated or any single study.
- 20 of Vertex Pharmaceuticals Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cystic Fibrosis is the condition Vertex Pharmaceuticals Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cystic Fibrosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vertex Pharmaceuticals Incorporated pipeline card: 191 registered trials from official public datasets.Report a data error.